Table 1 Baseline patient characteristics and information on types and number of premedications
Variables | Transit group (N = 62) | Failure-to-Transit group (N = 38) | P value | rho (P value) | |
|---|---|---|---|---|---|
Age (years) | 35 (29.8 ‒ 42.3) [18:64] | 41 (33.8 ‒ 49.0) [22:71] | 0.064 | 0.186 (0.064) | |
Female gender | 31 (81.6) | 48 (77.4) | 0.620 | -0.05 (0.624) | |
Weight (kg) | 128.5 (112.0 ‒ 141.5) [74.6:243] | 116.5 (100.0 ‒ 137.3) [81:186] | 0.104 | -0.163 (0.104) | |
Height (cm) | 1.7 (1.7 ‒ 1.7) [1.5:1.9] | 1.7 (1.6 ‒ 1.7) [1.5:1.9] | 0.326 | -0.099 (0.329) | |
Body mass index (kg/m2) | 43.6 (40.5 ‒ 47.9) [27.4:82.1] | 40.5 (35.0 ‒ 46.6) [28.4:62.9] | 0.124 | -0.155 (0.125) | |
Diabetes or Haemoglobin A1c level > 5.7% | 7 (18.4) | 10 (16.1) | 0.767 | -0.03 (0.770) | |
Premedication lead time (min) | 80 (57.8 ‒ 140.0) [41:238] | 119.5 (85.0 ‒ 171.3) [30:365] | 0.006* | 0.277 (0.005)* | |
Type of premedication | |||||
 Tapentadol premedication tablets visualized in the gastric remnant | 1 tablet | 11 (28.9) | 27 (43.5) | 0.308 | -0.148 (0.147) |
2 tablets | 27 (71.1) | 34 (54.8) | |||
4 tablets | 0 (0.0) | 1 (1.6) | |||
Netupitant/palonosetron premedication capsules visualized in the gastric remnant | None | 6 (15.8) | 5 (8.1) | 0.238 | 0.12 (0.235) |
1 capsule | 32 (84.2) | 57 (91.9) | |||
  Total number of premedications administered | |||||
Total premedications administered | 2 premedications | 17 (44.7) | 32 (51.6) | 0.751 | -0.058 (0.568) |
3 premedications | 21 (55.3) | 29 (46.8) | |||
5 premedications | 0 (0.0) | 1 (1.6) | |||